Primary Antibodies

  1. Schnellfilter:
  2. Zitierungen (318)
  3. Stark validiert (43)

Artikel 1 bis 20 von 372 gesamt

pro Seite
Seite:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Primärantikörper

Katalog-Nr. Wirt Iso. Klon Präs. Reakt. Anwendungen  

Alpha-Synuclein / SNCA Antikörper

IF staining of human neuroblastoma (SH-SY5Y) expressing endogenous α-synuclein Mouse IgG AS11 Alexa Fluor 488 Hu ICC/IF
0.1 mg / 530,00 €
  Dendritics SAS

Alpha-Synuclein / SNCA Antikörper

IF staining of human neuroblastoma (SH-SY5Y) expressing endogenous α-synuclein Mouse IgG AS11 Alexa Fluor 546 Hu ICC/IF
0.1 mg / 530,00 €
  Dendritics SAS

Alpha-Synuclein / SNCA Antikörper

IF staining of human neuroblastoma (SH-SY5Y) expressing endogenous α-synuclein Mouse IgG AS11 Alexa Fluor 647 Hu ICC/IF
0.1 mg / 530,00 €
  Dendritics SAS

Alpha-Synuclein / SNCA Antikörper

IF staining of human neuroblastoma (SH-SY5Y) expressing endogenous α-synuclein Mouse IgG AS11 HRP Hu C, WB
0.1 mg / 490,00 €
  Dendritics SAS

Alpha-Synuclein / SNCA Antikörper

IF staining of human neuroblastoma (SH-SY5Y) expressing endogenous α-synuclein Mouse IgG AS11 Purified Hu C, ICC/IF, WB
0.1 mg / 440,00 €
  Dendritics SAS

Anti-Remicade (Infliximab) Antikörper

Inhibition of Remicade binding to TNF - alpha. Mouse IgG1 108G4.03 Biotin Hu E(detection)
0.1 mg / 250,00 €
  Dendritics SAS

Anti-Remicade (Infliximab) Antikörper

Inhibition of Remicade binding to TNF - alpha. Mouse IgG1 108G4.03 Purified Hu E(caption)/E(detection), FN
0.1 mg / 230,00 €
  Dendritics SAS

Anti-Remicade(Infliximab) Antikörper

Elisa detection of Remicade with or without human serum DDX5001/DDX5002 - Biotin Mouse IgG1 103A8.03 Biotin Hu E(detection)
0.1 mg / 250,00 €
  Dendritics SAS

Anti-Remicade(Infliximab) Antikörper

Anti - Remicade (Anti - Infliximab) detection by competition ELISA in serum from Remicade (Infliximab) - treated polyarthritis rheumatoid patients. Mouse IgG1 103A8.03 Purified Hu E, FN
0.1 mg / 230,00 €
  Dendritics SAS

Basophils Antikörper

IHC staining of human tonsil epithelial crypts with clone 212H6 (DDX0030). Mouse IgM 212H6.16 Purified Hu C, F, WB
0.1 mg / 440,00 €
  Dendritics SAS

Basophils Antikörper

IHC staining of human skin frozen section with clone 212H6 (DDX0030) (normal skin) Mouse IgM 212H6.16 Alexa Fluor 488 Hu F
0.1 mg / 530,00 €
  Dendritics SAS

Basophils Antikörper

IHC staining of human skin frozen section with clone 212H6 (DDX0030) (normal skin) Mouse IgM 212H6.16 Alexa Fluor 546 Hu ICC/IF
0.1 mg / 530,00 €
  Dendritics SAS

Basophils Antikörper

Basophils Mouse IgM 212H6.16 Alexa Fluor 647 Hu F
0.1 mg / 530,00 €
  Dendritics SAS

Basophils Antikörper

IHC staining of human skin frozen section with clone 212H6 (DDX0030) (psoriasis) Mouse IgM 212H6.16 Biotin Hu F, ICC/IF
0.1 mg / 490,00 €
  Dendritics SAS

Beta-2-microglobulin Antikörper

COP5 transiently transfected with Beta-2-microglobulin cDNA stained by clone mAb4 Mouse IgM mAb4 Purified Hu E, E(capture), F
0.1 mg / 440,00 €
  Dendritics SAS

BETVIA allergen Bet v1 Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G27E9B1 Purified Pollen E, IP
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG3 H.G26F6B2.06 Purified Pollen E
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G11A9F3.03 Purified Pollen E
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G28C10.01 Purified Pollen E
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG1 H.G5F2A4.09 Purified Pollen E, WB
0.1 mg / 600,00 €
  Dendritics SAS

Artikel 1 bis 20 von 372 gesamt

pro Seite
Seite:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  • LinkedIn